Use of Akkermansia muciniphila for treating inflammatory conditions
AssigneeSchweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos
InventorsLiam O'Mahony, Cezmi A. Akdis, David Michalovich, Edith M. Hessel, James R. Brown, David N. Mayhew, Sorif Uddin
Life of this patent
Estimating the term…
Abstract
The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.
Claims15
A method for the treatment of airway inflammatory activity in a subject having an airway disorder, the method comprising:
- administration of one or more Akkermansia muciniphilia strains to the gastrointestinal tract of a subject having an airway disorder, wherein the airway inflammatory activity of an airway disorder is selected from the group consisting of asthma, infection-associated inflammation, allergen-induced inflammation, allergic rhinitis and chronic rhinosinusitis, thereby treating the airway inflammatory activity in the subject.
A method for treatment of airway inflammatory activity in a subject having an airway disorder, the method comprising:
- administration of one or more Akkermansia muciniphilia strains to the gastrointestinal tract of a subject having an airway disorder, wherein the airway inflammatory activity of the airway disorder is responsive to increased expression of ILT-4, thereby treating the airway inflammatory activity in the subject.
Dependencies are inferred from the claim text.